Srdjan Stankovic

Statistics

Publications

Citations

386

H-Index

Active since

2018

Affiliations

Acadia Pharmaceuticals (United States)(Current)

University of Exeter

Srdjan Stankovic is an author at Acadia Pharmaceuticals (United States) specializing in antipsychotic pharmacotherapy, psychopharmacology, and psychosis in alzheimer’s disease.

ORCID

Publications per year

2018–2021

Publications

Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study

Clive Ballard, Carol Banister, Zunera Khan et al. · The Lancet Neurology · 2018 · 188 citations

Medicine, Pharmacology, Psychiatry +15

Trial of Pimavanserin in Dementia-Related Psychosis

Pierre N. Tariot, Jeffrey L. Cummings, Maria Soto‐Martin et al. · New England Journal of Medicine · 2021 · 136 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms

Clive Ballard, James M. Youakim, Bruce Coate et al. · The Journal of Prevention of Alzheimer s Disease · 2019 · 40 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis

Clive Ballard, Bruce Coate, Victor Abler et al. · International Journal of Geriatric Psychiatry · 2020 · 22 citations · Full text

Medicine, Pharmacotherapy, Psychiatry +17

1–4 of 4